Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Gut

Volumn 66, Issue 9, 2017, Pages 1697-1708

  Ikenaga, Naoki ^a   Peng, Zhen Wei ^a,b   Vaid, Kahini A ^a   Liu, Susan B ^a   Yoshida, Shuhei ^a   Sverdlov, Deanna Y ^a   Mikels Vigdal, Amanda ^c   Smith, Victoria ^c   Schuppan, Detlef ^a,d   Popov, Yury V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GILEAD SCIENCES   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

CIRRHOSIS; HEPATIC FIBROSIS; HEPATITIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS

Indexed keywords

AB 0023; COLLAGEN; LYSYL OXIDASE LIKE 2; M 64; MONOCLONAL ANTIBODY; OXIDOREDUCTASE; UNCLASSIFIED DRUG; LOXL2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMICAL ANALYSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; COLLAGEN METABOLISM; CONTROLLED STUDY; CROSS LINKING; DISEASE COURSE; DRUG EFFICACY; DUCTULAR REACTION; ENZYME INHIBITION; HEPATIC PROGENITOR CELL; HEPATIC STELLATE CELL; HISTOLOGY; IN VITRO STUDY; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CONVALESCENCE; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECTS; LIVER CIRRHOSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL;

AMINO ACID OXIDOREDUCTASES; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPATOCYTES; LIVER CIRRHOSIS; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; RECOVERY OF FUNCTION; STEM CELLS;

EID: 85010379045     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312473     Document Type: Article

References (37)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
3. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009;50:1294-306.
4. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-48.
5. Popov Y, Sverdlov DY, Sharma AK, et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011;140:1642-52.
6. Liu SB, Ikenaga N, Peng ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J 2016;30:1599-609.
7. Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 2006;63:2304-16.
8. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012;12:540-52.
9. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17.
10. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 2005;43:499-507.
11. Ikenaga N, Liu SB, Sverdlov DY, et al. A new mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015;185:325-34.
12. Kwong GA, von Maltzahn G, Murugappan G, et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 2013;31:63-70.
13. Rodriguez HM, Vaysberg M, Mikels A, et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010;285:20964-74.
14. Rojkind M, Novikoff PM, Greenwel P, et al. Characterization and functional studies on rat liver fat-storing cell line and freshly isolated hepatocyte coculture system. Am J Pathol 1995;146:1508-20.
15. Xie G, Karaca G, Swiderska-Syn M, et al. Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology 2013;58:1801-13.
16. Popov Y, Sverdlov DY, Bhaskar KR, et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010;298:G323-34.
17. Popov Y, Patsenker E, Fickert P, et al. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro-and antifibrogenic genes. J Hepatol 2005;43:1045-54.
18. Popov Y, Patsenker E, Stickel F, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008;48:453-64.
19. Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-ß, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 2014;147:1378-92.
20. Peng ZW, Ikenaga N, Liu SB, et al. Integrin avß6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis. Hepatology 2016;63:217-32.
21. Dorrell C, Erker L, Schug J, et al. Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev 2011;25:1193-203.
22. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
23. Toyoda H, Kumada T, Tada T, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 2015;30:1183-9.
24. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013;57:230-6.
25. Li Z, Dranoff JA, Chan EP, et al. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007;46:1246-56.
26. Georges PC, Hui JJ, Gombos Z, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;293:G1147-54.
27. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998;15:259-69.
28. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-77.
29. Canesin G, Cuevas EP, Santos V, et al. Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. Oncogene 2015;34:951-64.
30. Herranz N, Dave N, Millanes-Romero A, et al. Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell 2012;46:369-76.
31. Lugassy J, Zaffryar-Eilot S, Soueid S, et al. The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. J Biol Chem 2012;287:3541-9.
32. Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013;494:247-50.
33. Perepelyuk M, Terajima M, Wang AY, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 2013;304: G605-14.
34. Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005;41:809-18.
35. Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133:80-90.
36. Patsenker E, Popov Y, Stickel F, et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008;135:660-70.
37. Kuramitsu K, Sverdlov DY, Liu SB, et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013;183:182-94.